Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New brain zapping technique shows promise for depression

NCT ID NCT05224206

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how a fast form of brain stimulation called iTBS affects the brains of 22 adults with major depression. Participants receive both real and fake stimulation in a blinded setup, followed by 6 weeks of daily treatment. The goal is to understand how iTBS changes brain activity and whether it can reduce depression symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 22 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men or women aged 18 to 55 years of age * Mini-International Neuropsychiatric Interview-confirmed diagnosis of MDD, as a single or recurring episode * Symptoms of MDD have not improved after ≥ 1 but ≤ 7 adequate dose(s) of antidepressant trial(s) in the current depressive episode * A baseline score of ≥ 15 on the 17-item Hamilton Rating Scale for Depression (HRSD-17) * Have received a stable antidepressant regimen for at least four weeks prior to entering trial * Are voluntary and competent to consent to study * Can speak and read English Exclusion Criteria: * Current or past (\< 3 months) substance (including nicotine) or alcohol abuse/dependence, as defined in DSM-5 criteria * Positive urine test for illegal substances, cannabis, or cotinine * Suicide attempt in the past three months and/or active suicidal intent * Pregnancy (confirmed by urine test) and/or lactation * Psychotic features in the current episode * Any comorbid mental health disorders (including, but not limited to lifetime history of psychotic disorders, OCD, PTSD and/or bipolar I or II disorder) with the exception of anxiety/panic disorders and ADHD * Significant unstable medical or neurologic illness confirmed by medical history and blood test at baseline (e.g. uncontrolled diabetes, or renal dysfunction) * Organic cause to the depressive symptoms (e.g. thyroid dysfunctions), as ruled out by the referring physician * Contraindication for TMS (e.g., personal history of epilepsy or convulsion, metallic head implant, pacemaker) * Contraindication for MRI (e.g. metallic implant, claustrophobia) * Have undergone a prior PET or SPECT research study * ECT or rTMS treatment in the current depressive episode * Benzodiazepine use * Have a body mass index (BMI) higher then 35 or lower then 18 * Any other condition that, in the opinion of the investigators, would adversely affect the participant's ability to complete the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depressive disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Royal Ottawa Mental Health Centre

    Ottawa, Ontario, K1Z 7K4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.